PCM
ENTA icon

Penserra Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Penserra Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-460
Closed -$26K – 1420
2021
Q3 		$26K Hold
460
– – ﹤0.01% 1206
2021
Q2 		$20K Hold
460
– – ﹤0.01% 1146
2021
Q1 		$22K Sell
460
-5
-1% -$249 ﹤0.01% 958
2020
Q4 		$19K Buy
465
+295
+174% +$13K ﹤0.01% 851
2020
Q3 		$7K Buy
+170
New +$8.24K ﹤0.01% 848

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Penserra Capital Management's ENTA Position: Q4 2021 in Review

Penserra Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2021, closing a stake of 460 shares — an estimated $26K sold.

Penserra Capital Management first reported a position in ENTA in Q3 2020 and held it in 5 quarters. The position peaked at $26K in Q3 2021. 179 funds tracked by Wall St. Rank hold ENTA as of Q4 2021.

  • Penserra Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 460 Enanta Pharmaceuticals shares in Q4 2021, an estimated $26K.
  • Penserra Capital Management first reported a position in Enanta Pharmaceuticals in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Enanta Pharmaceuticals position peaked at $26K in Q3 2021.
  • 179 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.